J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
J B Chemicals and Pharmaceuticals Ltd
Total Current Liabilities
J B Chemicals and Pharmaceuticals Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
|
Total Current Liabilities
₹6.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Current Liabilities
₹151B
|
CAGR 3-Years
24%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Current Liabilities
₹63B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Current Liabilities
₹234.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Total Current Liabilities
₹108.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
9%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Current Liabilities
₹44.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
J B Chemicals and Pharmaceuticals Ltd
Glance View
In the bustling marketplace of India's pharmaceutical industry, J B Chemicals and Pharmaceuticals Ltd. has carved its niche, a testament to its strategic vision and operational prowess. Founded in 1976 by Janak Mehta, the company has grown from its humble beginnings into a leading player in both the domestic and international arenas. Originally rooted in the ethos of quality and innovation, it established a firm foothold in the pharmaceutical sector through a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and contract manufacturing. As a vertically integrated company, J B Chemicals leverages its ability to control the manufacturing process from start to finish, ensuring strict quality measures and cost efficiencies, vital in tackling industry competition and regulatory challenges. The heart of J B Chemicals’ revenue model is its well-rounded product line that spans a range of therapeutic categories, including gastrointestinal, cardiovascular, and anticold segments. Blockbuster brands like Cilacar and Metrogyl have propelled the company to the top ranks within India, while its export division flourishes, contributing significantly to total earnings. With footprints in more than 30 countries, particularly in Russia and South Africa, the company taps into the growing demand for generic medicines worldwide. Moreover, by embracing innovation and investing in research and development, J B Chemicals continues to introduce new and improved medical solutions, positioning itself as a dynamic player in meeting global healthcare needs.
See Also
What is J B Chemicals and Pharmaceuticals Ltd's Total Current Liabilities?
Total Current Liabilities
6.7B
INR
Based on the financial report for Dec 31, 2025, J B Chemicals and Pharmaceuticals Ltd's Total Current Liabilities amounts to 6.7B INR.
What is J B Chemicals and Pharmaceuticals Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
14%
Over the last year, the Total Current Liabilities growth was 8%. The average annual Total Current Liabilities growth rates for J B Chemicals and Pharmaceuticals Ltd have been 7% over the past three years , 14% over the past five years .